{"denoms":[{"counts":[{"groupId":"BG000","value":"180"},{"groupId":"BG001","value":"181"},{"groupId":"BG002","value":"179"},{"groupId":"BG003","value":"540"}],"units":"Participants"}],"groups":[{"description":"Participants were initially randomized to receive pembrolizumab 2 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \\~66 months)","id":"BG000","title":"Pembrolizumab 2 mg/kg"},{"description":"Participants were initially randomized to receive pembrolizumab 10 mg/kg IV Q3W. With Amendment 03, this dosing was discontinued and all study participants were to be treated with fixed-dose open label pembrolizumab 200 mg IV Q3W. Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \\~66 months)","id":"BG001","title":"Pembrolizumab 10 mg/kg"},{"description":"Participants were initially randomized to receive 1 of 4 possible chemotherapy regimens decided at the treating institution (carboplatin+paclitaxel, paclitaxel alone, dacarbazine, or temozolomide). Participants were to receive study drug until discontinuation due to progression of disease, toxicity, or choice. (Up to \\~66 months)","id":"BG002","title":"Investigator-Choice Chemotherapy (ICC)"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.9","value":"59.5"},{"groupId":"BG001","spread":"13.3","value":"60.1"},{"groupId":"BG002","spread":"12.7","value":"60.5"},{"groupId":"BG003","spread":"13.6","value":"60.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"72"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"213"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"109"},{"groupId":"BG002","value":"114"},{"groupId":"BG003","value":"327"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"97"},{"groupId":"BG002","value":"98"},{"groupId":"BG003","value":"294"}],"title":"PD-L1 Positive"},{"measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"134"}],"title":"PD-L1 Negative"},{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"41"},{"groupId":"BG003","value":"112"}],"title":"Unknown"}]}],"description":"Membranous PD-L1 expression in tumor and tumor-associated immune cells was assessed by immunohistochemistry assay and scored on a unique melanoma (Allred Proportion Score \\[APS\\]/Melanoma \\[MEL\\]) scale of 0 to 5 points. Participants with an APS score of ≥2 (membranous staining in ≥1% of cells) were considered to be PD-L1 Positive and participants with an APS score of 0 or 1 were considered to be PD-L1 Negative.","paramType":"COUNT_OF_PARTICIPANTS","title":"Programmed Cell Death-Ligand 1 (PD-L1) Tumor Expression Status","unitOfMeasure":"Participants"}],"populationDescription":"The baseline analysis population consisted of all randomized participants. Participants were included in the group to which they were initially randomized for Baseline Characteristics."}